Leadsynbio
Suzhou · Founded 2015
About Leadsynbio
Founded in 2015, Leadsynbio is a nationally recognized "Little Giant" enterprise, one of top performers among specialized, high-end and innovation-driven SMEs that provide distinctive products or services. Headquartered in Suzhou Industrial Park, we have established R&D centers in Suzhou and the United States, and operate modern, internationally compliant manufacturing facilities in Hunan and Anhui Provinces, creating a strategic layout integrating innovative R&D, lean manufacturing, and global supply. Leadsynbio focuses on the development and industrialization of proprietary synthetic biology technologies. Powered by a self-built synthetic biology platform, we have successfully developed multiple breakthrough biosynthesis technologies. Through vertically integrated capabilities across the entire value chain, we ensure high-efficiency, large-scale production and stable global supply of core products to customers across numerous countries and regions. We are committed to developing transformative biomanufacturing processes that significantly reduce production costs and carbon emissions, promote low-carbon manufacturing, and enhance environmental sustainability, empowering our partners to build green competitive advantages. Guided by our mission of 'To lead smart and green manufacturing through synthetic biology technologies',Leadsynbio drives bioeconomy industrial upgrades with original innovation and global presence, acting as a key force in achieving global carbon neutrality.
Company Facts
- Founded: 2015
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $50K – $100K
- Total funding: $50.5M
- Funding stage: Late Stage Venture
- Last round: Series D (Jul 2025)
- Website: https://www.leadsynbio.com/
- Phone: +86 0512-62955029
Industries & Categories
Biopharma, Biotechnology, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/leadsynbio-43091 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.